Liquid biopsy as effective as tissue biopsy for non-small cell lung cancer

Researchers have revealed that a liquid biopsy test called Guardant360®, is comparable to standard tissue biopsies in detection of guideline recommended biomarkers in advanced non-small cell lung cancer (NSCLC), has a faster turn-around time, and has the potential to support identification of more patients who can be treated with targeted therapy.

Leave a Reply

Your email address will not be published.